Castleman's disease medical therapy

Jump to navigation Jump to search

Castleman's disease Microchapters

Home

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Castleman's disease from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Castleman's disease medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Castleman's disease medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Castleman's disease medical therapy

CDC on Castleman's disease medical therapy

Castleman's disease medical therapy in the news

Blogs on Castleman's disease medical therapy

Directions to Hospitals Treating Castleman's disease

Risk calculators and risk factors for Castleman's disease medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Raviteja Guddeti, M.B.B.S. [2]

Overview

Medical Therapy

Unicentric

Multicentric

There is no standard therapy for MCD at the moment.

It is important to distinguish AIDS-related Multicentric Castleman’s disease from other forms of Multicentric Castleman’s disease. Treatment for the former can be focused upon the same protocols used for treating the underlying AIDS.[3]

Recent work with HIV-positive patients with KSHV-related MCD suggests that treatment with the antiherpesvirus drug ganciclovir or the antiCD20 B cell monoclonal antibody, rituximab, may markedly improve outcome. These drugs target and kill B cells via the B cell specific CD20 marker. Since B cells are required for the production of antibodies, the body's immune response is weakened whilst on treatment and the risk of further viral or bacterial infection is increased. Due to the uncommon nature of the condition there are not many large scale research studies from which standardized approaches to therapy may be drawn, and the extant case studies of individuals or small cohorts should be read with caution. As with many diseases, the patient's age, physical state and previous medical history with respect to infections may impact on the disease progression and outcome.

Use of tocilizumab has been proposed.[4]

Siltuximab, a monoclonal antibody that binds interleukin-6, is currently being investigated in a Phase II clinical trial.[5]

Other treatments for multicentric castleman disease include the following:

References

  1. name=pmid21934347
  2. Talarico F, Negri L, Iusco D, Corazza GG (2008). "Unicentric Castleman's disease in peripancreatic tissue: case report and review of the literature". G Chir. 29 (4): 141–4. PMID 18419976. Unknown parameter |month= ignored (help)
  3. Sprinz E, Jeffman M, Liedke P, Putten A, Schwartsmann G (2004). "Successful treatment of AIDS-related Castleman's disease following the administration of highly active antiretroviral therapy (HAART)". Ann. Oncol. 15 (2): 356–8. doi:10.1093/annonc/mdh066. PMID 14760135. Unknown parameter |month= ignored (help)
  4. Matsuyama M, Suzuki T, Tsuboi H; et al. (2007). "Anti-interleukin-6 receptor antibody (tocilizumab) treatment of multicentric Castleman's disease" (– Scholar search). Intern. Med. 46 (11): 771–4. doi:10.2169/internalmedicine.46.6262. PMID 17541233.[dead link]
  5. A Study to Evaluate the Safety of Long-term Treatment With Siltuximab in Patients With Multicentric Castleman's Disease ClinalTrails.gov.
  6. http://www.mayoclinic.com/health/castleman-disease/DS01000/DSECTION=treatments-and-drugs

de:Morbus Castleman

Template:WS